Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,464 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation.
Johansson H, Guerrieri-Gonzaga A, Gandini S, Bertelsen BE, Macis D, Serrano D, Mellgren G, Lazzeroni M, Thomas PS, Crew KD, Kumar NB, Briata IM, Galimberti V, Viale G, Vornik LA, Aristarco V, Buttiron Webber T, Spinaci S, Brown PH, Heckman-Stoddard BM, Szabo E, Bonanni B, DeCensi A. Johansson H, et al. NPJ Breast Cancer. 2024 Jan 18;10(1):7. doi: 10.1038/s41523-024-00616-8. NPJ Breast Cancer. 2024. PMID: 38238336 Free PMC article.
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.
Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P, Torrisi R, Cazzaniga M, Mora S, Sandri MT, Pelosi G, Luini A, Goldhirsch A, Lien EA, Veronesi U. Decensi A, et al. Among authors: johansson h. J Natl Cancer Inst. 2003 Jun 4;95(11):779-90. doi: 10.1093/jnci/95.11.779. J Natl Cancer Inst. 2003. PMID: 12783932 Free article. Clinical Trial.
Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, Perloff M, Malone WF, Formelli F. Decensi A, et al. Among authors: johansson h. Clin Cancer Res. 2003 Oct 15;9(13):4722-9. Clin Cancer Res. 2003. PMID: 14581342 Clinical Trial.
A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.
Decensi A, Bonanni B, Baglietto L, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Robertson C, Marinucci I, Mariette F, Sandri MT, Daldoss C, Bianco V, Buttarelli M, Cazzaniga M, Franchi D, Cassano E, Omodei U. Decensi A, et al. Among authors: johansson h. Clin Cancer Res. 2004 Jul 1;10(13):4389-97. doi: 10.1158/1078-0432.CCR-04-0087. Clin Cancer Res. 2004. PMID: 15240527 Clinical Trial.
Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.
Serrano D, Baglietto L, Johansson H, Mariette F, Torrisi R, Onetto M, Paganuzzi M, Decensi A. Serrano D, et al. Among authors: johansson h. Clin Cancer Res. 2005 Mar 1;11(5):2083-8. doi: 10.1158/1078-0432.CCR-04-1549. Clin Cancer Res. 2005. PMID: 15756035 Clinical Trial.
Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
Guerrieri-Gonzaga A, Robertson C, Bonanni B, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Formelli F, Intra M, Latronico A, Franchi D, Pelosi G, Johnson K, Decensi A. Guerrieri-Gonzaga A, et al. Among authors: johansson h. J Clin Oncol. 2006 Jan 1;24(1):129-35. doi: 10.1200/JCO.2005.02.9934. J Clin Oncol. 2006. PMID: 16382122 Clinical Trial.
1,464 results